German researchers have tracked down the causes for central nervous system side effects of cancer immunotherapies and blocked them in small animal models.
Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
Researchers at University Hospital Hamburg-Eppendorf have laid the foundation to screen for molecules that shift Th17 cells from proinflammatory or immune-dampening mode.
GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.
ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.
Viennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab.
DefiniGEN Ltd., and Atelerix Ltd. have successfully shipped in vitro liver models from the UK to the US without freezing them thus preventing cell damage and loss-of function.
With the opening of a production centRE for RNA vaccines and therapeutics, German CDMO Wacker Biotech is expanding its expertise in the field of RNA active ingredients.
Drug discovery CRO Evotec SE announced has entered into a partnership with Inserm, Lille University Hospital and Inserm Transfert to screen new biomarkers and targets in obesity and metabolic diseases.